Skip to content

Feasibility of Interventions on People Who Inject Drugs in Vietnam

Feasibility of an Interventional Project to Reduce HIV Incidence Among People Who Inject Drugs in Haiphong, Viet Nam

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02573948
Acronym
DRIVE-IN
Enrollment
603
Registered
2015-10-12
Start date
2014-09-30
Completion date
2016-06-30
Last updated
2018-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis Virus, HIV, Substance Abuse

Keywords

People who inject drugs, Vietnam, Community support groups

Brief summary

This study aims at assessing the feasibility of implementing an interventional cohort of people who inject drugs in Haiphong, Viet Nam. For this purpose, the investigators will conduct a RDS survey to i) assess the current situation of drug use behaviour, HIV and Hepatitis C Virus (HCV) infection in the study population and ii) recruit participants for the longitudinal phase. The latter will consist of enroling the most difficult to reach People Who Inject Drugs (PWID) (those not followed by health centers), including early injectors, Men who have Sex with Men (MSM) and female sex workers (FSW) and following them up for 6 months in order to estimate the follow-up rate and preliminary estimates of HIV and HCV incidence.

Detailed description

Objectives: The primary objective of the DRIVE-IN project is to evaluate the feasibility of implementing an interventional cohort of PWID in Haiphong. Such a cohort (DRIVE) will be instrumental in demonstrating the efficacy of a community-involved intervention integrating prevention and care in order to reduce HIV and HCV transmission among PWID in Haiphong. The main expected result of DRIVE-IN is to demonstrate that enrolment and follow-up of various hard-to-reach subgroups of PWID is feasible in the local context. These feasibility objectives will be evaluated using a set of relevant indicators. Design: The research will first include a respondent-driven sampling (RDS) survey, including a maximum of 600 PWID. Then 250 RDS participants (i.e about a quarter of the future DRIVE cohort) will be selected for a longitudinal study, with an enrolment and 3 follow-up visits at week 4, 12 and 24. In parallel, four qualitative studies will be implemented: one study to explore how to reach the hardest-to-reach and most-at-risk PWID, one feed-back study on PWID feeling about their participation in the research, one study investigating the reasons of drop-outs, and a final study on the research process itself. Endpoints: The RDS will describe the target population and the patterns of drug use. The feasibility of implementing an interventional cohort will be evaluated on several indicators: * International multi-disciplinary research network is operational * Completion of recruitment within the time frame * Follow-up rate \>80% at 24 weeks * Implementation and increased access to peer-led interventions * Establishment of a data management center * Improved laboratory capacities for research * Documented support of local and national authorities Study population RDS survey Inclusion criteria Age \> 18 years Self-reported drug injector confirmed by a positive urinary test and either skin marks of injection or knowledge of injecting procedures Signed informed consent Non-inclusion criteria Unable of understanding informed consent and answering questionnaires Longitudinal study Inclusion criteria Having participated to the RDS survey Signed informed consent specific to the longitudinal study Non-inclusion criteria Ongoing Methadone Maintenance Therapy (MMT) Ongoing antiretroviral therapy Health status not compatible with study follow-up Have a plan to move out of Haiphong over the next two years. Have been sentenced recently to a prison term Follow-up and study visits contents: Participants of the longitudinal phase will be followed at week 4, 12 and 24 (final visit). During the RDS, face-to-face questionnaires will be applied on drug use, sexual health, and referral to care and repeated at each follow-up visit, along with the record of medical events. In addition, a urinary test will be collected at the RDS to assess the range of recent drugs used, and repeated at the final follow-up visit (week 24). Finally, at the RDS and final visit, HIV, HCV, Hepatitis B Virus (HBV) serology will be done along with appropriate counselling. Sample size: * 603 PWID will be enrolled in the RDS survey * 250 RDS participants will be enroled in the longitudinal phase, including: * 140 PWID for \> 2 years, including females * 50 recent injectors (\< 2 years from first injection) * 30 FSW who inject drugs * 30 MSM who inject drugs

Interventions

OTHERno intervention is assessed

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
ANRS, Emerging Infectious Diseases
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Inclusion criteria * Being more than 18 years of age * Being drug injector confirmed by a positive urine drug test with knowledge of injecting procedures * Having signed the informed consent form * For the Longitudinal study - having participated in the RDS survey *

Exclusion criteria

* Unable to understand informed consent and how to answer a questionnaire * For the longitudinal study - being under methadone maintenance therapy and antiretroviral treatment * Having a health condition not compatible with study follow-up * Plan to move away from Haiphong in the next 2 years * Serving a sentence in prison

Design outcomes

Primary

MeasureTime frameDescription
Number of Cohort Participants Attending the Last Follow-up Visit at W5252 weeksNumber of participants who were followed up and not lost to follow-up after enrolment into cohort.

Secondary

MeasureTime frameDescription
HIV Seroconversion52 weeksNumber of new HIV infection among HIV negative (at RDS) cohort participants over 1 year period.
HCV Seroconversion52 weeksNumber of new HCV infection among HCV negative (at RDS) cohort participants over 1 year period
Incidence of HCV Infection52 weeksThe HCV incidence was calculated by 100person/year
HIV Incidence52 weeksHIV incidence was calculated by 100person/year. With zero conversion, we choose 2.5% unilateral confidence interval.

Countries

Vietnam

Participant flow

Recruitment details

People Who Injected Drugs (PWID), age \> 18 years, with history of injecting drug use confirmed by a positive urine test and visual inspection of injection marks

Participants by arm

ArmCount
PWID RDS
603 participants
603
Total603

Withdrawals & dropouts

PeriodReasonFG000
Longitudinal CohortDeath9
Longitudinal CohortIncarcerated25
Longitudinal CohortLost to Follow-up22

Baseline characteristics

CharacteristicPWID RDS
Age, Continuous36.5 years
STANDARD_DEVIATION 8.4
Currently under Methadone Maintenance Therapy36 Participants
Duration of Injection use8 years
HCV positive398 Participants
HIV positive152 Participants
Injecting drug: heroin alone602 Participants
Injection with syringe already used by someone else (last 3 months)33 Participants
Medical Insurance105 Participants
Number of drug injection (typical day)2.7 injection per day
STANDARD_DEVIATION 1
Region of Enrollment
Vietnam
603 participants
Sex: Female, Male
Female
61 Participants
Sex: Female, Male
Male
542 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
9 / 250
other
Total, other adverse events
0 / 250
serious
Total, serious adverse events
9 / 250

Outcome results

Primary

Number of Cohort Participants Attending the Last Follow-up Visit at W52

Number of participants who were followed up and not lost to follow-up after enrolment into cohort.

Time frame: 52 weeks

Population: Participants were invited to follow-up visits at W4, W12, W24 and W52

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PWID CohortNumber of Cohort Participants Attending the Last Follow-up Visit at W52194 Participants
Secondary

HCV Seroconversion

Number of new HCV infection among HCV negative (at RDS) cohort participants over 1 year period

Time frame: 52 weeks

Population: HCV negative cohort participants with HCV test result available at W24 and/or W52.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PWID CohortHCV Seroconversion18 Participants
Secondary

HIV Incidence

HIV incidence was calculated by 100person/year. With zero conversion, we choose 2.5% unilateral confidence interval.

Time frame: 52 weeks

Population: HIV negative cohort participants with HCV test result available at W24 a/or W52

ArmMeasureValue (NUMBER)
PWID CohortHIV Incidence0 infections per 100 person-years
Secondary

HIV Seroconversion

Number of new HIV infection among HIV negative (at RDS) cohort participants over 1 year period.

Time frame: 52 weeks

Population: HIV negative cohort participants with HIV test result available at W24 and/or W52.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PWID CohortHIV Seroconversion0 Participants
Secondary

Incidence of HCV Infection

The HCV incidence was calculated by 100person/year

Time frame: 52 weeks

Population: HCV negative cohort participants with HCV test result available at W24 a/or W52

ArmMeasureValue (NUMBER)
PWID CohortIncidence of HCV Infection19.4 infections per 100 person-years

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026